['To evaluate in anti-HCV-positive patients the clinical impact of the rs35761398 variant of the CNR2 gene leading to the substitution of Gln (Q) of codon 63 of the cannabinoid receptor 2 (CB2) with Arg (R).', '253 consecutive anti-HCV-/HCV-RNA-positive patients were enrolled, of whom 53 were HCV carriers with persistently normal ALT (PNALT group) and 200 had a history of steadily abnormal serum ALT values (abnormal ALT group). All patients were naive for antiviral therapy and were screened for the CNR2 rs35761398 polymorphism by a TaqMan assay.', 'Subjects in the PNALT group, compared with those in the abnormal ALT group were older (58.5±12 vs. 50.7±12.4 years, p\u200a=\u200a0.001), more frequently female (66% vs. 42%, p\u200a=\u200a0.003), with lower body mass index (BMI) (24.5±3.1 vs. 26.6±4.6, p\u200a=\u200a0.003), and more frequently with HCV genotype 2 (43.1% vs 17.7%, p\u200a=\u200a0.0002) and CB2-63 QQ variant (34% vs. 11%, p\u200a=\u200a0.0001). Considering all 253 patients, no difference in the demographic, biochemical, or virological data was observed between patients in the different CB2-63 variants. The logistic regression analysis identified CB2-63 QQ, HCV genotype 2, older age and lower BMI as independent predictors of PNALT (p<0.00001).'] Is cannabinoid receptor 2-63 QQ variant associated with persistently normal aminotransferase serum levels in chronic hepatitis C?